- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01243138
Africa and Middle East Cardiovascular Epidemiological Study (ACE)
Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region
연구 개요
상세 설명
This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained.
Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Accra, 가나
- Pfizer Investigational Site
-
Jachie-Ashanti, 가나
- Pfizer Investigational Site
-
Kumasi, 가나
- Pfizer Investigational Site
-
Sogakope V/R, 가나
- Pfizer Investigational Site
-
Takoradi, 가나
- Pfizer Investigational Site
-
-
-
-
-
Abuja, FCT, 나이지리아
- Pfizer Investigational Site
-
Abuja, Garki, 나이지리아
- Pfizer Investigational Site
-
Calabar, 나이지리아
- Pfizer Investigational Site
-
Enugu, 나이지리아
- Pfizer Investigational Site
-
Keffi, Nassarawa, 나이지리아
- Pfizer Investigational Site
-
-
-
-
-
Kwa-Zulu Natal, 남아프리카, 4091
- Pfizer Investigational Site
-
Rondebosch, 남아프리카, 7700
- Pfizer Investigational Site
-
-
Gauteng
-
Halfway House, Gauteng, 남아프리카, 1685
- Pfizer Investigational Site
-
-
Kwazulu-natal
-
Sydenham, Durban, Kwazulu-natal, 남아프리카, 4091
- Pfizer Investigational Site
-
-
Limpopo
-
Mokopane, Limpopo, 남아프리카, 0600
- Pfizer Investigational Site
-
Sheshego, Limpopo, 남아프리카, 0742
- Pfizer Investigational Site
-
-
Pretoria
-
Mamelodi East, Pretoria, 남아프리카, 0122
- Pfizer Investigational Site
-
-
-
-
-
Beirut, 레바논
- Pfizer Investigational Site
-
Jbeil, Lebanon, 레바논
- Pfizer Investigational Site
-
Jounieh, 레바논
- Pfizer Investigational Site
-
Tripoli, 레바논
- Pfizer Investigational Site
-
-
-
-
-
Dammam, 사우디 아라비아
- Pfizer Investigational Site
-
Jeddah, 사우디 아라비아
- Pfizer Investigational Site
-
Jeddah 21573, 사우디 아라비아
- Pfizer Investigational Site
-
Makkah, 사우디 아라비아
- Pfizer Investigational Site
-
Riyadh, 사우디 아라비아
- Pfizer Investigational Site
-
Riyadh, 사우디 아라비아, 11584
- Pfizer Investigational Site
-
Yanbu, 사우디 아라비아
- Pfizer Investigational Site
-
-
-
-
-
Kebemer, 세네갈
- Pfizer Investigational Site
-
Kedoungou, 세네갈
- Pfizer Investigational Site
-
Saint Louis, 세네갈
- Pfizer Investigational Site
-
Ziguinchor, 세네갈
- Pfizer Investigational Site
-
-
Nabil Choucair
-
Dakar, Nabil Choucair, 세네갈
- Pfizer Investigational Site
-
-
Ouakam
-
Dakar, Ouakam, 세네갈
- Pfizer Investigational Site
-
-
-
-
-
Abu Dhabi, 아랍 에미리트
- Pfizer Investigational Site
-
Al Ain, 아랍 에미리트
- Pfizer Investigational Site
-
Dubai, 아랍 에미리트
- Pfizer Investigational Site
-
Ras Al Khaima, 아랍 에미리트
- Pfizer Investigational Site
-
-
-
-
-
Alger, 알제리, 16015
- Pfizer Investigational Site
-
Bejaja, 알제리, 6000
- Pfizer Investigational Site
-
Djelfa, 알제리, 17000
- Pfizer Investigational Site
-
Laghouat, 알제리
- Pfizer Investigational Site
-
M'Sila, 알제리
- Pfizer Investigational Site
-
Relizane, 알제리, 48000
- Pfizer Investigational Site
-
Saida, 알제리, 20000
- Pfizer Investigational Site
-
Tebessa, 알제리
- Pfizer Investigational Site
-
Tlemcen, 알제리, 13000
- Pfizer Investigational Site
-
-
-
-
-
Amman, 요르단
- Pfizer Investigational Site
-
Irbid, 요르단
- Pfizer Investigational Site
-
Salt, 요르단
- Pfizer Investigational Site
-
-
-
-
-
Alexandria, 이집트
- Pfizer Investigational Site
-
Cairo, 이집트
- Pfizer Investigational Site
-
Shiben Al Kom, 이집트
- Pfizer Investigational Site
-
Tanta, 이집트
- Pfizer Investigational Site
-
-
-
-
-
Bafoussam, 카메룬
- Pfizer Investigational Site
-
Mbandjock, 카메룬
- Pfizer Investigational Site
-
Njombe, 카메룬
- Pfizer Investigational Site
-
Soa, 카메룬
- Pfizer Investigational Site
-
-
Cite Verte
-
Yaounde, Cite Verte, 카메룬
- Pfizer Investigational Site
-
-
Deido
-
Douala, Deido, 카메룬
- Pfizer Investigational Site
-
-
-
-
-
Chongoria, 케냐, 60401
- Pfizer Investigational Site
-
Nairobi, 케냐, 00508
- Pfizer Investigational Site
-
-
-
-
-
Adailiya, 쿠웨이트
- Pfizer Investigational Site
-
Fahaheel, 쿠웨이트
- Pfizer Investigational Site
-
Kuwait, 쿠웨이트
- Pfizer Investigational Site
-
Mishref, 쿠웨이트
- Pfizer Investigational Site
-
Qadesya, 쿠웨이트
- Pfizer Investigational Site
-
Yarmouk, 쿠웨이트
- Pfizer Investigational Site
-
-
-
-
-
Ariana, 튀니지, 2073
- Pfizer Investigational Site
-
Bouficha, 튀니지, 4010
- Pfizer Investigational Site
-
Messaadine, 튀니지, 4013
- Pfizer Investigational Site
-
Sfax, 튀니지, 3013
- Pfizer Investigational Site
-
Tunis, 튀니지, 1000
- Pfizer Investigational Site
-
Zaghouan, 튀니지, 1100
- Pfizer Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Adult aged 18 or above
Exclusion Criteria:
- Pregnant women and/or lactating mothers
- Subjects presenting with any life threatening disease/condition
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension
기간: At the time of the first visit
|
At the time of the first visit
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.
기간: At the time of the first visit
|
At the time of the first visit
|
Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.
기간: At the time of the first visit
|
At the time of the first visit
|
Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.
기간: At the time of the first visit
|
At the time of the first visit
|
Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.
기간: At the time of the first visit
|
At the time of the first visit
|
Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.
기간: At the time of the first visit
|
At the time of the first visit
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Hamoui O, Omar MI, Raal FJ, Rashed W, Kane A, Alami M, Abreu P, Mashhoud W, Alsheikh-Ali AA. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 Mar 15;19(1):61. doi: 10.1186/s12872-019-1034-2.
- Brouri M, Ouadahi N, Nibouche D, Benabbas Y, El Hassar M, Bouraoui S, Abad N, Abreu PC, Ikardouchene L. [Cardiovascular risk factors in Algeria. Analysis of the subgroup from the "Africa/Middle East Cardiovascular Epidemiological" Study]. Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):61-66. doi: 10.1016/j.ancard.2018.01.003. Epub 2018 Mar 9. French.
- Raal FJ, Alsheikh-Ali AA, Omar MI, Rashed W, Hamoui O, Kane A, Alami M, Abreu P, Mashhoud WM. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health. 2018 Feb 12;76:15. doi: 10.1186/s13690-018-0257-5. eCollection 2018.
- Ahmed AM, Hersi A, Mashhoud W, Arafah MR, Abreu PC, Al Rowaily MA, Al-Mallah MH. Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc. 2017 Oct;29(4):235-243. doi: 10.1016/j.jsha.2017.03.004. Epub 2017 Mar 14.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .